文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

PSD3作为食管鳞状细胞癌免疫格局和肿瘤侵袭性的一种上下文依赖性调节因子。

PSD3 as a context-dependent modulator of immune landscape and tumor aggressiveness in esophageal squamous cell carcinoma.

作者信息

Luo Shujuan, Li Huifang, Cai Bangwu, Nurbahati Aididar, Cui Hong, Peng Tianyuan, Wang Wei, Liu Qing, Lu Xiaomei, Zheng Shutao

机构信息

State Key Laboratory of Pathogenesis, Prevention, Treatment of Central Asian High Incidence Diseases, Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

出版信息

Front Immunol. 2025 Aug 15;16:1641254. doi: 10.3389/fimmu.2025.1641254. eCollection 2025.

DOI:10.3389/fimmu.2025.1641254
PMID:40895529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12394057/
Abstract

In this study, we investigated PSD3, CD274 (PD-L1), and TNFSF18 as potential immune-related biomarkers in esophageal squamous cell carcinoma (ESCC) using integrative transcriptomic and experimental approaches. CD274 and TNFSF18 were consistently up-regulated in ESCC across both TCGA and GEO datasets, while PSD3 showed significantly higher expression in TCGA but no significant difference in the GEO cohort. Only PSD3 demonstrated a significant association with overall survival, with higher expression correlating with improved prognosis. Interestingly, despite its favorable prognostic value, PSD3 functionally promoted ESCC cell proliferation, invasion, and migration , while inversely regulating PD-L1 expression. Conversely, heterozygous knockout of PD-L1 in KYSE150 cells impaired tumor aggressiveness. Co-immunoprecipitation revealed a direct physical interaction between PSD3 and PD-L1, suggesting a regulatory axis with implications for immune evasion. These findings position PSD3 as a context-dependent immuno-oncogenic factor and a potential therapeutic target in ESCC.

摘要

在本研究中，我们采用整合转录组学和实验方法，研究了PSD3、CD274（PD-L1）和TNFSF18作为食管鳞状细胞癌（ESCC）潜在免疫相关生物标志物的情况。在TCGA和GEO数据集中，ESCC中CD274和TNFSF18均持续上调，而PSD3在TCGA中表达显著更高，但在GEO队列中无显著差异。只有PSD3与总生存期显著相关，表达越高，预后越好。有趣的是，尽管PSD3具有良好的预后价值，但其在功能上促进了ESCC细胞的增殖、侵袭和迁移，同时反向调节PD-L1的表达。相反，KYSE150细胞中PD-L1的杂合敲除损害了肿瘤侵袭性。免疫共沉淀揭示了PSD3与PD-L1之间存在直接的物理相互作用，提示存在一个与免疫逃逸相关的调节轴。这些发现表明PSD3是一种依赖于背景的免疫致癌因子，也是ESCC潜在的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/90cf3896c335/fimmu-16-1641254-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/4c84e0f26cee/fimmu-16-1641254-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/782775776b2a/fimmu-16-1641254-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/d101e0571eae/fimmu-16-1641254-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/2b7c29675d1c/fimmu-16-1641254-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/88a39514062b/fimmu-16-1641254-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/cdd66099848e/fimmu-16-1641254-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/a7017862fd1d/fimmu-16-1641254-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/684cbdaf562e/fimmu-16-1641254-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/aa2510d61025/fimmu-16-1641254-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/b4e9e2bdad84/fimmu-16-1641254-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/90cf3896c335/fimmu-16-1641254-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/4c84e0f26cee/fimmu-16-1641254-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/782775776b2a/fimmu-16-1641254-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/d101e0571eae/fimmu-16-1641254-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/2b7c29675d1c/fimmu-16-1641254-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/88a39514062b/fimmu-16-1641254-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/cdd66099848e/fimmu-16-1641254-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/a7017862fd1d/fimmu-16-1641254-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/684cbdaf562e/fimmu-16-1641254-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/aa2510d61025/fimmu-16-1641254-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/b4e9e2bdad84/fimmu-16-1641254-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5264/12394057/90cf3896c335/fimmu-16-1641254-g011.jpg

相似文献

[1]
PSD3 as a context-dependent modulator of immune landscape and tumor aggressiveness in esophageal squamous cell carcinoma.

Front Immunol. 2025-8-15

[2]
Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.

Br J Cancer. 2025-6-10

[3]
WISP1 drives esophageal squamous cell carcinoma progression via modulation of cancer-associated fibroblasts and immune microenvironment.

Front Immunol. 2025-7-23

[4]
PSD3, regulated by PKM2, endows growth and metastasis advantages in esophageal squamous cell carcinoma by modulating EMT progression.

Sci Rep. 2025-7-2

[5]
PTGDS deficiency as a driver of M2 macrophage polarization and immunosuppressive microenvironment in esophageal squamous cell carcinoma: an experimental study.

Int J Surg. 2025-8-1

[6]
SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization.

Front Immunol. 2025-6-19

[7]
Identification of CTSC-driven progression in ESCC by single-cell sequencing and experimental validation.

Front Immunol. 2025-7-16

[8]
Identification of an individualized immune-related miRNA pair signature for survival prediction of neoadjuvant chemoradiotherapy in esophageal squamous cell cancer.

Cancer Lett. 2025-10-1

[9]
PANoptosis-driven molecular stratification in esophageal squamous cell carcinoma: A multi-omics prognostic model and FGFR-Targeted therapeutic validation.

Comput Biol Med. 2025-9

[10]
Single-Cell Transcriptomics Reveals STAT1 Drives LHPP Downregulation in Esophageal Squamous Cell Carcinoma Progression.

Technol Cancer Res Treat. 2024

本文引用的文献

[1]
A Pilot Study: Contrasting Genomic Profiles of Lung Adenocarcinoma Between Patients of European and Latin American Ancestry.

Int J Mol Sci. 2025-5-19

[2]
Radiomics applications in the modern management of esophageal squamous cell carcinoma.

Med Oncol. 2025-5-27

[3]
Correcting scale distortion in RNA sequencing data.

BMC Bioinformatics. 2025-1-28

[4]
GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy.

Mol Ther. 2025-6-4

[5]
A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.

Cell Death Dis. 2024-9-10

[6]
How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art.

Biomedicines. 2024-7-12

[7]
Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma.

Cancers (Basel). 2024-7-22

[8]
NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma.

Immunology. 2024-10

[9]
Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy: a retrospective cohort study.

J Thorac Dis. 2024-6-30

[10]
Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.

Biochim Biophys Acta Mol Cell Res. 2024-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索